ALNY Financial Facts
Net revenues from research collaborators: 8.71MOther (expense) income: 229K
See Full Income Statement
Other long-term liabilities: 1.78M
Total current liabilities: 70.58M
See Full Balance Sheet
Alnylam Pharmaceuticals, Inc. (ALNY) Earnings
|
Expand Research on ALNY
| Next EPS Date | 8/6/21 *Est. | EPS Growth Rate | -7.9% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +6.1% | Revenue Growth Rate | +78.5% *Last Qtr. |
| Average % Move 1-Wk after EPS | -7.8% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 4/29/21 |  |
Q121 | -$1.64 | -$1.75 | +$0.11 | $177.6M | $168.74M | N/A |  | | Details |
| 2/11/21 | |
Q420 | -$1.60 | -$1.76 | +$0.16 | $163.6M | $146.07M | N/A | | | Details |
| 11/5/20 | |
Q320 | -$1.58 | -$1.66 | +$0.08 | $125.9M | $120.75M | N/A | | | Details |
| 8/6/20 | |
Q220 | -$1.67 | -$1.74 | +$0.07 | $104M | $99.48M | N/A | | | Details |
| 5/6/20 | |
Q120 | -$1.52 | -$1.89 | +$0.37 | $99.5M | $91.56M | N/A | | | Details |
| 2/6/20 | |
Q419 | -$1.98 | -$2.22 | +$0.24 | $71.68M | $71.92M | N/A | | | Details |
| 10/31/19 | |
Q319 | -$1.50 | -$2.04 | +$0.54 | $70.1M | $56.41M | N/A | | | Details |
| 8/6/19 | |
Q219 | -$2.02 | -$1.86 | -$0.16 | $44.7M | $69.2M | N/A | | | Details |
